The MATCH program has existed at Rigshospitalet for several years, encompassing all patients receiving solid organ transplants or bone marrow transplants. MATCH has succeeded in lowering the risk of severe CMV infection post transplant to single digit percentages, thereby reducing morbidity as well as cost.
PERSIMUNE incorporates and extends the MATCH surveillance of clinical and paraclinical data. The iatrogenic immunodeficiency sustained by transplant recipients varies with type of organ and time after transplant , allowing longitudinal studies of infection risk at several levels of immunodeficiency.
The Transplant/MATCH SIG will bring together clinicians from all specialities involved in organ transplant activities.
To formulate specific projects along the guidelines of the PM collaboration, exploiting both the retrospective MATCH cohorts as well as the prospective PM cohorts.